Targeted immunotherapy of cancer: Development of antibody-induced cellular immunity

Journal of Pharmacy and Pharmacology

Volumn 55, Issue 2, 2003, Pages 163-167

  Lu, Yingjuan ^b   Low, Philip S ^a  

^a PURDUE UNIVERSITY   (United States)

^b Endocyte Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CANCER ANTIBODY; CANCER VACCINE; FOLIC ACID; FOLIC ACID FLUORESCEIN CONJUGATE; GPI 0100; HAPTEN; HAPTEN ANTIBODY; IDIOTYPIC ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 2; MONOCLONAL ANTIBODY; OLIGONUCLEOTIDE; QS 21; RITUXIMAB; SAPONIN DERIVATIVE; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER REGRESSION; CANCER TISSUE; CELL SURFACE; CELLULAR IMMUNITY; CLINICAL PROTOCOL; DRUG COST; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG RECEPTOR BINDING; HUMAN; HUMORAL IMMUNITY; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NOTE;

ANIMALS; ANTIBODIES, NEOPLASM; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; NEOPLASMS;

EID: 0344406995     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/002235702540     Document Type: Note

References (37)

1. Amigorena, S. (2002) Fc gamma receptors and cross-presentation in dendritic cells. J. Exp. Med. 195: F1-3
2. Anderson, C.F., Mosser, D. M. Cutting edge: Biasing immune responses by directing antigen to macrophage Fc gamma receptors. J. Immunol. 168: 3697-3701
3. Baselga, J., Albanell, J., Molina, M. A., Arribas, J. (2001) Mechanism of action of trastuzumab and scientific update. Semin. Oncol. 28: 4-11
4. Bhattacharya-Chatterjee, M., Chatterjee, S. K., Foon, K. A. (2001) The anti-idiotype vaccines for immunotherapy. Curr. Opin. Mol. Ther. 3: 63-69
5. Booth, J. W., Kim, M. K., Jankowski, A., Schreiber, A. D., Grinstein, S. (2002) Contrasting requirements for ubiquitylation during Fc receptor-mediated endocytosis and phagocytosis. Embo. J. 21: 251-258
6. Brossart, P., Wirths, S., Brugger, W., Kanz, L. (2001) Dendritic cells in cancer vaccines. Exp. Hematol. 29: 1247-1255
7. Clynes, R., Takechi, Y., Moroi, Y., Houghton, A., Ravetch, J. V. (1998) Fc receptors are required in passive and active immunity to melanoma. Proc. Natl Acad. Sci. USA 95: 652-656
8. Dhodapkar, K. M., Krasovsky, J., Williamson, B., Dhodapkar, M. V. (2002) Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. 195: 125-133
9. Dyall, R., Vasovic, L. V., Clynes, R. A., Nikolic-Zugic, J. (1999) Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor. Eur. J. Immunol. 29: 30-37
10. Falo, L. D., Kovacsovics-Bankowski, M., Thompson, K., Rock, K. L. (1995) Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat. Med. 1: 649-653
11. Hsueh, E. C. (2001) Tumour cell-based vaccines for the treatment of melanoma. BioDrugs 15: 713-720
12. Kalish, R. S., Wood, J. A. (1997) Induction of hapten-specific tolerance of human CD8+ urushiol (poison ivy)-reactive T lymphocytes. J. Invest. Dermatol. 108: 253-257
13. Kessels, H. W., Wolkers, M. C., Schumacher, T. N. (2002) Adoptive transfer of T-cell immunity. Trends Immunol. 23: 264-269
14. Kreitman, R. J., Wilson, W. H., Bergeron, K., Raggio, M., Stetler-Stevenson, M., FitzGerald, D. J., Pastan, I. (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 345: 241-247
15. Kroesen, B. J., McLaughlin, P. M., Schuilenga-Hut, P. H., Jacobs, S. C., Molema, G., Helfrich, W., De Leij, L. F. (2002) Tumor-targeted immune complex formation: Effects on myeloid cell activation and tumor-directed immune cell migration. Int. J. Cancer 98: 857-863
16. Linenberger, M. L., Maloney, D. G., Bernstein, I. D. (2002) Antibody-directed therapies for hematological malignancies. Trends Mol. Med. 8: 69-76
17. Lu, Y., Low, P. S. (2002) Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol. Immunother. 51: 153-162
18. Maloney, D. G., Smith, B., Rose, A. (2002) Rituximab: Mechanism of action and resistance. Semin. Oncol. 29: 2-9
19. Manjili, M. H., Wang, X. Y., Park, J., Facciponte, J. G., Repasky, E. A., Subjeck, J. R. (2002) Immunotherapy of cancer using heat shock proteins. Front. Biosci. 7: d43-52
20. Mitchell, M. S. (2002) Cancer vaccines, a critical review - Part I. Curr. Opin. Investig. Drugs 3: 140-149
21. Morse, M. A. (2000) Technology evaluation: Gene therapy (IL-2), Valentis Inc. Curr. Opin. Mol. Ther. 2: 448-452
22. Nawrocki, S., Wysocki, P. J., Mackiewicz, A. (2001) Genetically modified tumour vaccines: An obstacle race to break host tolerance to cancer. Expert Opin. Biol. Ther. 1: 193-204
23. Nishioka, Y., Hua, W., Nishimura, N., Sone, S. (2002) Genetic modification of dendritic cells and its application for cancer immunotherapy. J. Med. Invest. 49: 7-17
24. Ross, J. F., Chaudhuri, P. K., Ratnam, M. (1994) Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73: 2432-2443
25. Ruf, P., Lindhofer, H. (2001) Induction of a long-lasting anti-tumor immunity by a trifunctional bispecific antibody. Blood 98: 2526-2534
26. Schultze, J., Nadler, L. M., Gribben, J. G. (1996) B7-mediated costimulation and the immune response. Blood Rev. 10: 111-127
27. Schuurhuis, D. H., Laban, S., Toes, R. E., Ricciardi-Castagnoli, P., Kleijmeer, M. J., Van Der Voort, E. I., Rea, D., Offringa, R., Geuze, H. J., Melief, C. J., Ossendorp, F. (2000) Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J. Exp. Med. 192: 145-150
28. Schuurhuis, D. H., Ioan-Facsinay, A., Nagelkerken, B., Van Schip, J. J., Sedlik, C., Melief, C. J., Verbeek, J. S., Ossendorp, F. (2002) Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J. Immunol. 168: 2240-2246
29. Selenko, N., Maidic, O., Draxier, S., Berer, A., Jager, U., Knapp, W., Stockl, J. (2001) CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia 15: 1619-1626
30. Sondel, P. M., Hank, J. A. (2001) Antibody-directed, effector cell-mediated tumor destruction. Hematol. Oncol. Clin. North Am. 15: 703-721
31. Thomas, A. K., June, C. H. (2001) The promise of T-lymphocyte immunotherapy for the treatment of malignant disease. Cancer J. 7 (Suppl. 2): S67-75
32. Toffoli, G., Cernigoi, C., Russo, A., Gallo, A., Bagnoli, M., Boiocchi, M. (1997) Overexpression of folate binding protein in ovarian cancers. Int. J. Cancer 74: 193-198
33. Vasovic, L. V., Dyall, R., Clynes, R. A., Ravetch, J. V., Nikolic-Zugic, J. (1997) Synergy between an antibody and CD8+ cells in eliminating an established tumor. Eur. J. Immunol. 27: 374-382
34. Wallace, P. K., Tsang, K. Y., Goldstein, J., Correale, P., Jarry, T. M., Schlom, J., Guyre, P. M., Ernstoff, M. S., Fanger, M. W. (2001) Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class I. J. Immunol. Methods 248: 183-194
35. Weitman, S. D., Frazier, K. M., Kamen, B. A. (1994) The folate receptor in central nervous system malignancies of childhood. J. Neurooncol. 21: 107-112
36. Withoff, S., Helfrich, W., De Leij, L. F., Molema, G. (2001) Bi-specific antibody therapy for the treatment of cancer. Curr. Opin. Mol. Ther. 3: 53-62
37. Zum Buschenfelde, C. M., Hermann, C., Schmidt, B., Peschel, C., Bernhard, H. (2002) Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res. 62: 2244-2247